Anaveon AG

Swiss Biotech Association

Member

Anaveon is a late pre-clinical phase biotech based in Basel, Switzerland. It focuses on the development of next generation IL-2 based therapeutic antibodies for tumor immunotherapy in melanoma, kidney carcinoma and lung cancer.

Products, services, technology

ANV419

Location

Hochbergerstrasse 60C, 4057 Basel, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2017
Number of employees in Switzerland

10-19

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

GlycoEra AG

GlycoEra leverages its control over natural glycan-mediated pathways to advance novel drugs using its propriety platform, the CustumGlycan Platform. GlycoEra develops first in class therapeutics in inflammatory disease, autoimmune disorder and immuno-oncology indications.
8952 Schlieren

Member

JFG Life Sciences Stiftung der Universität Basel

Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. We invest in companies in Switzerland or abroad that are active in the field of life sciences. We value strong founding teams and high-quality science.
4051 Basel

Member

Swizzard Pharma AG

Headquartered in Zug, Switzerland, Swizzard Pharma AG's mission is to support pharma/biotech companies in setting up a smart & lean Swiss infrastructure. We build on long-term partnership and offer a quality approach to maximize the value of your medical breakthroughs in Switzerland.
6300 Zug

Member